Ouxia 90 Tablet contains Etoricoxib 90 mg, a selective cyclooxygenase-2 (COX-2) inhibitor used primarily for the management of pain and inflammation associated with various musculoskeletal and inflammatory conditions. Etoricoxib exerts its therapeutic effects by selectively inhibiting the COX-2 enzyme, which plays a key role in the synthesis of prostaglandins involved in pain and inflammation, while sparing COX-1, thereby reducing gastrointestinal side effects commonly seen with non-selective NSAIDs. Ouxia 90 is indicated for the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis, providing effective relief from joint pain, swelling, and stiffness. It is also utilized for managing chronic musculoskeletal pain and postoperative dental pain. The recommended dosage should be individualized based on the patient’s condition and response to therapy, with careful consideration of contraindications such as hypersensitivity to Etoricoxib, active peptic ulcer disease, severe hepatic or renal impairment, and cardiovascular risk factors. Patients should be monitored for potential adverse effects, including hypertension, edema, and gastrointestinal discomfort. Ouxia 90 should be used at the lowest effective dose for the shortest duration necessary to minimize risks. It is essential to consult a healthcare professional before initiating therapy to ensure appropriate use and monitoring.